Clinical trial
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With…
NCT00131638 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00131638 |
|---|---|
| Title | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer |
| Official title | Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Placebo, Palifermin |
| Enrollment | 241 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Jul 1, 2016 |
| First posted | Aug 19, 2005 |
| Last update posted | Dec 16, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: